Genmab — December 2020

Helge_LarsenPI-redaktør

God morgen.

Klarussen

En vel i dag
endnu mere aktuel artikel fra 2016, sjovt her i slutningen af 2020 at læse den igen: https://www.proinvestor.com/boards/74456

E_L

Epcoritamab has entered the EMA paper-mountain... 3.1.40. Epcoritamab - EMEA-002907-PIP01-20
Treatment of mature B-cell lymphoma / Treatment of paediatric patients with
relapsed/refractory aggressive mature B-cell lymphoma
Day 30 discussion
Action: For discussion
Oncology https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-8-11-december-2020-meeting_en.pdf

E_L

Ofa is in there also for MS

bongobob

Why paediatric? The current Epco studies does not include children

E_L

it is probably to get a product-specific waiver by the Paediatric Committee so that they don't have to take care of any specific paediatric regulations ; that seems to be the 'normal' route for many of these drugs

Helge_LarsenPI-redaktør

God morgen.

Helge_LarsenPI-redaktør

Mandagens aviser med Pandora, Mærsk og Danske Bank: https://www.proinvestor.com/investornyt/670532/mandagens-aviser-med-pandora-maersk-og-danske-bank

Helge_LarsenPI-redaktør

Aktier/tendens: Fokus på fredagens
trækheste i ventet rød åbning. https://www.proinvestor.com/investornyt/670538/aktier-tendens-fokus-pa-fredagens-traekheste-i-ventet-rod-abning

E_L

This case emphasizes that, with the availability of novel immunotherapy agents (Daratumumab), and repurposed use of bortezomib, a patient with HIV‐negative relapsed PBL can be treated successfully https://onlinelibrary.wiley.com/doi/10.1002/ccr3.3673

E_L

Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication https://endpts.com/best-selling-tagrisso-further-outpaces-an-upcoming-jj-rival-winning-approval-in-new-nsclc-indication/

E_L

Why GPRC5D is a promising target for multiple myeloma https://multiplemyelomahub.com/medical-information/why-gprc5d-is-a-promising-target-for-multiple-myeloma

E_L

New trial - Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis (TIMIOS) https://clinicaltrials.gov/ct2/show/NCT04676555

E_L

This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosi ; Novartis wants to proof it takes less time with Kesimpta...

Solsen

Well they are still agressive. Good to se

AaBforever

Bølgegangen fortsætter...er onsdag med recepttal?

E_L

aggressive is good as long as they don't get too aggressive and start arbitration

bibob

E L.

bibob

Do you love Genmab Press 1 . - don't you like Genmab Press 2 . ??!! We are Sorry , but the press 2 buttom are not available. !! Try again tomorrow . Sleep well.

Helge_LarsenPI-redaktør

God morgen.